Letter from Genentech to Patients Regarding Tecentriq

On November 28, 2022, Genetech, a member of the Roche Group, announced the voluntary withdrawal of the U.S. indication for Tecentriq for the treatment of adult patients with certain types of bladder and urinary tract cancer (urothelial carcinoma that has spread or cannot be removed by surgery in patients who are not able to take cisplatin chemotherapy and have cancer that tests positive for “PD-L1”, or in patients who are not able to take chemotherapy that contains any platinum regardless of “PD-L1” status).

If you are currently receiving Tecentriq for bladder or urinary tract cancer, you should talk to your doctor about what the withdrawal means for you and your current treatment. You should discuss with your doctor the risks and the benefits of treatment with Tecentriq.

The full text letter from Genentech to patients.

Genentech’s press release has more information about the withdrawal.